Table 4.

Global time to peak systolic strain (% of the cardiac cycle length) of all patients with left ventricular hypertrophy (LVH), patients with LVH and confirmed etiology of hypertrophic cardiomyopathy (LVH+HCM+) and patients with LVH and a mimicking cardiomyopathy state (LVH+HCM–).

		LVH+HCM+	LVH+HCM–
	All patients	HCM	All LVH+HCM–	CA	AFD	HTNcm
Global parameter	(N = 163)	(N = 85)	(N = 78)	(N = 18)	(N = 30)	(N = 30)	p-Value	AUC (95% CI)
Circumferential
Subendocardium (%)	42.3 ± 5.6	41.4 ± 5.1	43.2 ± 5.9*	41.4 ± 6.5	42.4 ± 4.8	45.2 ± 6.1**	<0.05	0.59 (0.50–0.68)
Subepicardium (%)	40.2 ± 5.6	39.5 ± 5.2	40.9 ± 5.9	39.4 ± 6.1	40.1 ± 5.1	42.6 ± 6.4**	0.1	–
Transmural (%)	41.6 ± 5.4	40.6 ± 5.0	42.7 ± 5.6**	41.2 ± 5.8	41.6 ± 4.6	44.7 ± 6.1***	<0.01	0.62 (0.53–0.72)
Longitudinal
Subendocardium (%)	42.6 ± 5.1	42.5 ± 5.2	42.8 ± 5.1	42.4 ± 7.2	42.0 ± 4.5	43.8 ± 4.2	0.5	–
Subepicardium (%)	41.4 ± 5.4	41.3 ± 5.6	41.6 ± 5.2	40.3 ± 6.6	41.4 ± 4.6	42.7 ± 4.9	0.5	–
Transmural (%)	42.2 ± 5.1	42.0 ± 5.3	42.5 ± 5.0	42.0 ± 6.0	41.8 ± 4.4	43.5 ± 4.8	0.6	–
Radial
Transmural (%)	43.6 ± 5.6	43.5 ± 5.3	43.7 ± 6.0	43.0 ± 8.1	42.1 ± 4.6	45.7 ± 5.5	0.1	–
Minimum principal
Subendocardium (%)	41.4 ± 4.8	41.7 ± 4.6	41.1 ± 4.9	39.9 ± 5.7	40.7 ± 4.2	42.3 ± 5.1	0.3	–
Subepicardium (%)	41.0 ± 4.8	41.4 ± 5.0	40.6 ± 4.5	39.4 ± 6.8	40.6 ± 3.7	41.4 ± 3.5	0.4	–
Transmural (%)	41.1 ± 4.7	41.5 ± 4.7	40.6 ± 4.6	39.4 ± 6.1	40.5 ± 4.0	41.3 ± 4.2	0.4	–
Maximum transmural
Transmural (%)	43.3 ± 5.0	43.1 ± 4.9	43.6 ± 5.2	43.2 ± 6.8	42.4 ± 4.3	45.0 ± 4.8*	0.1	–

AFD, Anderson–Fabry disease; CA, cardiac amyloidosis; CI, confidence Interval; HCM, hypertrophic cardiomyopathy; HTNcm, hypertensive hypertrophy; LVH, left-ventricular hypertrophy.

Vs. HCM:

^*<0.05.

^**<0.01.

^***<0.001.

**** <0.0001.

Bold values are used for specific headers or p-Values lower than 0.05 (i.e. statistical significance).